Paradromics just cleared a major regulatory hurdle that puts it on track to compete directly with Neuralink in the brain-computer interface race. The Austin startup announced Thursday it received FDA approval to begin human trials of its speech-restoration implant early next year, marking a pivotal moment for the emerging neural interface industry.
Paradromics just scored the regulatory win that could reshape the brain-computer interface landscape. The FDA's approval announcement on Thursday puts the Austin-based startup in direct competition with Neuralink, which has already implanted at least 12 people worldwide with its device. The race to restore speech for paralyzed patients is heating up, and Paradromics is betting on superior bandwidth to win.
The company's Connexus implant represents a fundamentally different approach than its rivals. While Neuralink uses a quarter-sized chip with robotic insertion, Paradromics deploys a dime-sized metal disk with 421 microwire electrodes that surgeons can insert using an EpiPen-like instrument. "Individual neurons are the information carriers in the brain. So the more individual neurons you can record from, the more data you have," CEO Matt Angle explained to WIRED.
The technical specs tell a compelling story. In sheep trials, Paradromics achieved a 200-bits-per-second data transfer rate according to recent scientific preprint data. That's 25 times faster than Neuralink's claimed record of eight bits per second for cursor control, though the companies are measuring different tasks. Jacob Robinson from Motif Neurotech, another BCI company, expects Paradromics to "break the bandwidth record yet again" when human trials begin.
The human trial starting early 2025 will focus on two participants who've lost the ability to speak due to severe motor impairment. Unlike mind-reading science fiction, the system decodes brain signals from the motor cortex when users attempt to move their muscles to speak. Participants will try to say words out loud, and those words will appear on screen at an expected rate of 60 words per minute - roughly half normal speaking speed but fast enough for sustained conversation.
Paradromics plans to leverage AI voice cloning technology to give patients back their original voice, assuming existing recordings exist. "They will just try to say words, and those words will appear very quickly on a screen. They'll press play, and the words will be read in their own voice," Angle told WIRED. The company already tested brief 10-minute implantation in a surgical patient earlier this year without speech restoration functionality.
The competitive landscape is crowded but differentiated. Synchron, Precision Neuroscience, and Cognixion are pursuing less invasive approaches that read signals from the brain's surface or outside the skull entirely. The tradeoff is lower signal quality and data rates since these devices sit farther from the neurons they're monitoring.
This FDA approval comes as the broader brain-computer interface market accelerates beyond academic prototypes into commercial development. Robinson from Motif Neurotech draws parallels to consumer tech evolution: "That's the kind of shift we're seeing, where we had these academic prototypes, and now that we're on an industrial track, we should expect performance improvements in the same way we see iPhones released every few years."
After collecting safety and efficacy data from the first two participants for a full year, Paradromics plans to request FDA permission to expand the study. The company is targeting the estimated 5.4 million Americans living with paralysis, many of whom have lost the ability to communicate effectively. With Neuralink already demonstrating cursor control and basic communication in its patients, the pressure is on Paradromics to prove its bandwidth advantage translates into meaningfully better outcomes for users.
Paradromics' FDA approval marks a critical inflection point in the brain-computer interface revolution. With superior bandwidth claims and a streamlined surgical approach, the company is positioned to challenge Neuralink's early lead in neural implants. But the real test will be whether faster data transfer rates translate into better quality of life for paralyzed patients who've lost their voice. The next year of human trials will determine if Paradromics can deliver on its promise to give people back not just the ability to communicate, but to do so in their own voice.
